A Meta-Analysis Evaluating the Risk of Bleeding-Related Adverse Events with Defibrotide Treatment

IntroductionDefibrotide (DF) is approved for adult and pediatric patients with hepatic veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) with renal or pulmonary dysfunction after hematopoietic cell transplantation (HCT) in the United States. The recommended dose is 6.25 mg/kg every 6 hours given as a 2-hour intravenous (IV) infusion. In vitro, DF reduces activation of endothelial cells, promotes fibrinolytic enzymes, and exhibits...